PathologybioRxiv
Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis
T. Duparc, F. Briand, C. Trenteseaux…·L. O. Martinez
This study develops a 3-week dietary mouse model of NASH and shows liraglutide reduces hepatic steatosis and inflammation.
DOI 10.1152/ajpgi.00139.2019